Visible Particles in Parenteral Drug Products: A Review of Current Safety Assessment Practice
Spread the loveVisible Particles in Parenteral Drug Products: A Review of Current Safety Assessment Practice Visible particles (VPs) in parenteral drug products (PDPs) pose significant safety risks to patients and are a critical quality concern in the pharmaceutical industry. Despite technological advancements in particle detection and stringent regulatory controls, contamination with VPs remains a challenge….






